公开(公告)号：US20160207980A1

公开(公告)日：2016-07-21

申请号：US14916993

申请日：2014-09-05

Applicant: AMGEN INC.

Inventor： Zhimei DU ,  Pranhitha REDDY ,  Randal B. BASS ,  Feng HE ,  William C. FANSLOW, III ,  Yuling ZHANG ,  Da REN ,  Randal R. KETCHEM

IPC: C07K16/00

CPC classification number: C07K16/00 ,  C07K2317/14 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2319/30

Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.

Abstract translation: 本发明涉及具有有利于大规模生产含有这种变体Fc的治疗分子的糖基化特征的变体Fc-分子，例如抗体和Fc-融合分子。 本文描述的是改善糖基化成熟并使得含Fc分子例如Fc-融合分子和抗体的培养过程依赖性作用最小化的组合物和方法。 在Fc结构域内产生单个和多个氨基酸取代，目的是改善高甘露糖加工和糖基化成熟。

公开(公告)号：US20160032014A1

公开(公告)日：2016-02-04

申请号：US14777401

申请日：2014-03-14

Applicant: AMGEN INC.

Inventor： Mark Leo MICHAELS ,  Randal R. KETCHEM ,  Derek E. PIPER ,  Wei YAN ,  Chadwick Terence KING ,  Monique LaRae HOWARD

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting PCSK9 binding to LDLR and having increased pH sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind PCSK9 and have increased pH sensitivity, improved binding affinity and/or increased in vivos half life. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind PCSK9 Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from hypercholesterolemia and related disorders or conditions.

Abstract translation: 本发明提供与能够抑制PCSK9与LDLR结合并具有增加的pH敏感性，改善的结合亲和力和/或增加活体半衰期的抗原结合蛋白质有关或衍生的组合物和方法。 在实施方案中，抗原结合蛋白特异性结合PCSK9并具有增加的pH敏感性，改善的结合亲和力和/或增加活体半衰期。 在一些实施方案中，抗原结合蛋白是完全人，人源化或嵌合抗体，此类抗体的结合片段和衍生物，以及特异性结合PCSK9的多肽其他实施方案提供编码此类抗原结合蛋白的核酸及其片段和衍生物， 和多肽，包含此类多核苷酸的细胞，制备此类抗原结合蛋白的方法及其片段和衍生物，以及多肽，以及使用此类抗原结合蛋白，其片段及其衍生物和多肽的方法，包括治疗或诊断受试者的方法 来自高胆固醇血症和相关疾病或病症。

公开(公告)号：US20140274874A1

公开(公告)日：2014-09-18

申请号：US14207178

申请日：2014-03-12

Applicant: AMGEN INC.

Inventor： Randal R. KETCHEM ,  Jason Charles O'NEILL ,  Jeonghoon SUN

IPC: C07K14/47

CPC classification number: C07K14/8146 ,  A61K38/00

Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

Abstract translation: 公开了TIMP-3突变蛋白，变体和衍生物，编码它们的核酸，以及制备和使用它们的方法。